Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Correspondence] Ovarian cancer screening: UKCTOCS trial

We commend the UKCTOCS team on a remarkably well conducted trial,1 but conclude that screening technologies are not very effective in reducing ovarian cancer mortality. The primary endpoint was not achieved and we have reservations about the secondary analyses. The authors state that annual multimodal screening (MMS) significantly reduced ovarian cancer mortality after excluding either deaths in the first 7 years after randomisation or prevalent cancers. Although it might be reasonable to exclude deaths within 2 years to allow for occult cancers that were already advanced at randomisation, exclusion of all deaths in years 0–7 is hard to justify.